Pasithea Therapeutics (KTTA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Sep, 2026Opening remarks and agenda
Meeting held virtually, allowing stockholders to exercise full rights as in-person attendees.
Introductions included CEO, CFO, independent accountants, and corporate counsel.
Agenda included voting on three proposals: election of directors, ratification of auditors, and a reverse stock split.
Corporate governance
Record date for voting was July 24, 2026, with 33,414,448 shares outstanding, each entitled to one vote.
Quorum confirmed, enabling the meeting to proceed with official business.
Inspector of Elections appointed and proxies received in advance.
Board and executive committee updates
Dr. Tiago Reis Marques and Professor Lawrence Steinman nominated as Class 3 directors to serve until 2029.
No other director nominations were received.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Pasithea Therapeutics
- PAS-004 targets NF1 and cancer with promising early data, aiming to fill major unmet needs.KTTA
Corporate presentation - PAS-004 shows promising safety, efficacy, and market potential as a next-gen MEK inhibitor.KTTA
Corporate presentation - Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M.KTTA
Q2 2026 - Key votes include director elections, auditor ratification, and a reverse stock split to retain Nasdaq listing.KTTA
Proxy filing - PAS-004 shows strong safety, efficacy, and market potential for NF1 and solid tumors.KTTA
Corporate presentation - Key votes include director elections, auditor ratification, and a reverse stock split to avoid delisting.KTTA
Proxy filing - PAZ004 shows promising safety, efficacy, and market potential in NF1 and advanced cancer trials.KTTA
Oppenheimer 36th Annual Healthcare Life Sciences Conference - Net loss improved to $13.9M as PAS-004 advanced, but additional funding is needed for operations.KTTA
Q4 2024 - 2025 net loss increased to $20.4M, but cash rose to $55.2M as PAS-004 advanced in clinical trials.KTTA
Q4 2025